Processa Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 13
- Market Cap
- -
- Introduction
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Conditions
- Breast CancerTNBC - Triple-Negative Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06568692
- Locations
- 🇺🇸
Northwest Cancer Center, Dyer, Indiana, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT05270460
- Locations
- 🇺🇸
Torrance Clinical Research Institute, Inc., Lomita, California, United States
🇺🇸TriWest Research Associates, San Diego, California, United States
🇺🇸APF Research, LLC, Miami, Florida, United States
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
- Conditions
- Advanced CancerRefractory CancerTumor Gastric
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT04861987
- Locations
- 🇺🇸
Processa Clinical Site, Fairfax, Virginia, United States
A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04800562
- Locations
- 🇺🇸
Processa Clinical Site, Milwaukee, Wisconsin, United States
Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03836222
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
- Prev
- 1
- 2
- Next
News
Processa Pharmaceuticals Advances PCS6422 in Phase 2 Breast Cancer Trial with $7 Million Funding Boost
Processa Pharmaceuticals is developing PCS6422, a lead oncology asset currently in Phase 2 clinical trials for breast cancer treatment.
Processa Pharmaceuticals Secures $452.5M Licensing Deal for Gastroparesis Drug PCS12852
Processa Pharmaceuticals has entered into a binding term sheet with Intact Therapeutics for the exclusive licensing of PCS12852, a 5-HT4 receptor agonist targeting gastroparesis and gastrointestinal motility disorders.
Processa Pharmaceuticals Doses First Patient in Phase II Trial of NGC-Cap for Metastatic Breast Cancer
Processa Pharmaceuticals has dosed the first patient in a Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) for advanced or metastatic breast cancer.